Show simple item record

dc.contributor.authorEdmunds, Kim
dc.contributor.authorScuffham, Paul
dc.contributor.authorReeves, Penny
dc.contributor.authorGalvão, Daniel A
dc.contributor.authorTaaffe, Dennis R
dc.contributor.authorNewton, Robert U
dc.contributor.authorSpry, Nigel
dc.contributor.authorJoseph, David
dc.contributor.authorTuffaha, Haitham
dc.date.accessioned2021-07-01T03:41:07Z
dc.date.available2021-07-01T03:41:07Z
dc.date.issued2021
dc.identifier.issn0961-5423
dc.identifier.doi10.1111/ecc.13479
dc.identifier.urihttp://hdl.handle.net/10072/405508
dc.description.abstractProstate cancer (PCa) patients with bone metastases tend to have significant functional impairment from long-term androgen deprivation therapy (ADT), exacerbated by subsequent treatments such as second-line hormone therapies (abiraterone and enzalutamide), first- and second-line chemotherapy or immunotherapies (Hart et al., 2017). They are at significant risk of falls, fractures and consequent hospitalisation. There is a growing body of evidence to support the effectiveness of exercise in addressing the adverse effects of advanced PCa treatment (Hayes et al., 2019). Despite recommendations for men with bone metastases to participate in supervised exercise, there is often a reticence on the part of clinicians and/or patients due to concerns of fragility fracture or other adverse effects (Hart et al., 2017). These men with significant treatment toxicity and a high disease burden are an important patient group for whom exercise has been demonstrated to improve quality of life (QoL) (Galvão et al., 2018). To inform policy and improve accessibility of exercise for advanced PCa patients, it is important to determine whether such interventions represent value for money.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherWiley
dc.relation.ispartofjournalEuropean Journal of Cancer Care
dc.subject.fieldofresearchNursing
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchcode4205
dc.subject.fieldofresearchcode3211
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4206
dc.subject.keywordscost-effectiveness analysis
dc.subject.keywordseconomic evaluation
dc.subject.keywordsexercise medicine
dc.subject.keywordsmetastatic prostate cancer
dc.subject.keywordsvalue of information analysis
dc.titleDemonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationEdmunds, K; Scuffham, P; Reeves, P; Galvão, DA; Taaffe, DR; Newton, RU; Spry, N; Joseph, D; Tuffaha, H, Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer, European Journal of Cancer Care, 2021
dcterms.dateAccepted2021-03-23
dc.date.updated2021-06-28T23:30:37Z
dc.description.versionAccepted Manuscript (AM)
gro.description.notepublicThis publication has been entered as an advanced online version in Griffith Research Online.
gro.rights.copyright© 2021 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer, European Journal of Cancer Care, 2021, which has been published in final form at https://doi.org/10.1111/ecc.13479. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorScuffham, Paul A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record